Bharat Biotech asked to submit complete phase 2 data of its COVID-19 vaccine before phase 3 trial

According to officials, the Hyderabad-based vaccine maker applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to conduct phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3nCYiEI
via IFTTT